Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

MD, considering that breast cancer has a proven history with the FDA of advancing quickly in combination with companion diagnostics I could see it doing the same with bavi and Janssen's' CellSearch technology. Remember that Peregrine stated they wanted a partner to help expedite the development of breast and/or liver. So, presumably they would want to be on board for the start of the phase 2 trial. With nab-Paclitaxel taking the market lead in triple negative breast it would be advisable for Celgene (possibly teaming up with Janssen) to make a pre-emptive strike should the phase I data for this notoriously hard-to-treat population show promise and if there's been dialogue with the FDA for surrogate endpoints like apoptotic CTCs to be used, as they are in the phase I trial.

As we wait for the games, people die. I hope Dr. Stopek understands that.